2025.Dec.05

Corporate

OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma

OBI-902 Receives Second Orphan Drug Designations, Strengthening Its Clinical and Commercial Potential

HOMEWhat’s NewNewsOBI-902 Receives Consecutive FDA Orphan Drug Designation Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Nov.16

OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma.